Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M

Phio Pharmaceuticals Corp.

Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.
H.C. Wainwright receives a 3.0% commission on gross proceeds; company reimburses up to $75,000 in legal fees.
No obligation to sell any shares; sales are made on Nasdaq Capital Market with T+1 settlement.
Company provides customary indemnification to the sales agent under the agreement.
The offering is registered under the company's existing S-3 shelf registration statement effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Phio Pharmaceuticals Corp. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at $6,360,000 (effective 2026-04-08).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: $6,360,000
Effective: 2026-04-08

Exact text from the filing

On April 8, 2026, Phio Pharmaceuticals Corp. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.0001 per share (the “Shares”). The offering and sale of up to $6,360,000 of the Shares pursuant to the Sales Agreement is being registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279557), which was declared effective by the Securities and Exchange Commission (“SEC”) on July 1, 2024, which includes a base prospectus, and an accompanying prospectus supplement filed with the SEC on April 8, 2026.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001437749-26-011761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.